Kirithiga Ramalingam

Intratumoral Injection of mRNA-2752 and Pembrolizumab for High-Risk Ductal Carcinoma In Situ: A Phase 1 Nonrandomized Clinical Trial Key Points Question Is intratumoral immunotherapy safe for high-risk ductal carcinoma in situ (DCIS), and is there a signal of efficacy?

Abstract Ductal carcinoma in situ (DCIS) constitutes an array of morphologically recognized intraductal neoplasms in the mammary ductal tree defined by an increased risk for subsequent invasive carcinomas at or near the site of biopsy detection. However, only 15-45% of untreated DCIS cases progress to invasive cancer, so criteria to predict progression are needed to avoid overtreatment. Furthermore, mechanisms of progression may yield targets for non-surgical therapy and cancer prevention.

Retrorectal cyst: proteus in the backyard—case series and literature review Kirithiga Ramalingam1, Caroline Fiser1, Quratulain Sabih2 and Ashwani Rajput1 1Department of Surgery, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA 2Department of Surgery, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA Correspondence to Dr Ashwani Rajput; arajput2{at}jhmi.edu Abstract Retrorectal cysts are cystic lesions located in the retrorectal space and...